Newsletter
Anupam Rasayan has completed the acquisition of 100% stake in US-based Jayhawk Fine Chemicals Corporation for $150 million.
Anupam Rasayan India specialises in the manufacturing of specialty chemicals, serving agrochemical, pharmaceutical, and personal care industries.
While Jayhawk Fine Chemicals, a CABB subsidiary, custom manufactures specialty chemicals crucial for electronics like smartphones, 5G, EVs and aerospace sectors.
What will the companies get: for Anupam, the acquisition unlocks immediate entry into the US market and connects the company with leading multinational customers. It also upgrades its polymer portfolio with premium products like anhydrides and polyimide intermediates.
These products are used to make high-performance materials found in semiconductors, aerospace components, heavy-duty machinery, 5G equipment, and advanced automotive parts.
Besides, Anupam Rasayan will now move forward in the value chain by manufacturing N-1 molecules for critical sectors. These are high-value ingredients that go into making the final chemical product.
For CABB Group, the divestment helps sharpen its focus on high-growth segments such as pharma and life sciences.
Big picture: the global pharma industry is feeling the heat: innovation is slowing, R&D costs are surging, and patent expiries are threatening older drugs. On top of that, companies are reworking supply chains to reduce dependence on China.
India, with its low-cost manufacturing, strong talent base, and the world’s highest number of US-FDA approved plants, is well-positioned to fill that gap as a trusted partner.
The Daily Brief by Zerodha
